Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg

Inclusion Criteria: 1. Aged between 18 and 65 (inclusive), regardless of gender; 2. Fibroscan ≤ 7.4kpa; 3. HBeAg-negative CHB patients: HBsAg positive, HBeAg negative, HBsAb negative and HBeAb positive before receiving NUC treatment and during screening in this study; 4. HBeAg-negative chronic hepatitis B patients without liver cirrhosis who have been viral-negative for more than 3 years after receiving NUC treatment, and they meet the 2017 EASL guideline discontinuation standard (HBV DNA is lower than the lower limit of detection, that is, \<20 IU/ml); 5. HBsAg≤1000 IU/ml; 6. Have the intention to stop taking the drug, and sign a written informed consent. Exclusion Criteria: 1. HBsAb positive during screening; 2. Patients with hepatitis B cirrhosis in the compensatory and decompensated stage: patients with a clear history of cirrhosis (imaging or histological evidence) or Child-Pugh score ≥5 before NUC treatment, or complications of cirrhosis in the decompensated stage such as ascites, hepatic encephalopathy, esophageal variceal hemorrhage, etc.; 3. Patients who are allergic to alpha interferon and its drug ingredients, and the researchers judge that alpha interferon is not suitable for patients; 4. Received immunomodulators (including interferon, etc.) within 1 year before screening; 5. Combined with HAV, HCV, HDV, HEV, HIV infection, alcoholic liver disease, genetic metabolic liver disease, drug liver disease, non-alcoholic fatty liver disease and other chronic liver diseases; 6. Combined with autoimmune diseases, including autoimmune liver disease, psoriasis, etc. 7. Patients with primary liver cancer or screening with AFP greater than 100 ng/ml and imaging findings indicating the possibility of malignant liver occupation; Or AFP greater than 100 ng/ml for 3 months; 8. Neutrophil count \< 1.5 x 109 cells /L or platelet count \< 90 x 109 cells /L; 9. Creatinine is 1.5 times higher than the upper limit of normal; 10. Patients with other malignant tumors (excluding cured patients); 11. Patients with serious diseases of heart, lung, kidney, brain, blood and other important organs; 12. Patients with severe neurological and psychiatric disorders (such as epilepsy, depression, mania, seizures, schizophrenia, etc.); 13. Control unstable diabetes, hypertension, thyroid disease, etc.; 14. Pregnant and lactating women or patients who had pregnancy plans during the study period and did not want to use contraception; 15. Participate in other clinical investigators; 16. Patients who were not considered suitable for participation in this study by the investigators.